Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US

Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.“The completion of the INSPiRE-ICU 1 study marks a true milestone for Sedana Medical. Launching the randomized controlled multicenter studies across the

K-Fastigheter divests a property portfolio in Denmark

K-Fast Holding AB (”K-Fastigheter”) has signed an agreement with an institutional investor regarding the divestment of a property portfolio comprising 311 apartments in Denmark. On March 7[th], 2024, it was announced in a press release that K-Fastigheter had signed a letter of intent with an institutional investor regarding the divestment of a property portfolio comprising 311 apartments in Denmark. The parties have now signed an agreement, subject to conditions being fulfilled, under which K-Fastigheter will transfer the properties during the month of June 2024. The transaction is

OKEA ASA: Fixed Income Investor Meetings for Contemplated Senior Secured Bond

(Trondheim, 25 April, 2024): OKEA ASA (OSE: OKEA) ("OKEA" or the "Company") has mandated DNB Markets, a part of DNB Bank ASA, and Pareto Securities AS as Joint Global Coordinators and Joint Bookrunners and Arctic Securities AS as Joint Bookrunner to arrange a series of fixed income investor meetings commencing today. A new 4-year senior secured bond with an initial issue amount of USD 125 million may follow, subject to inter alia market conditions. Net proceeds from the contemplated bond issue will be used to fund planned investments related to the recently sanctioned Bestla (previously

AutoStore publishes 2024 annual report

(Nedre Vats, 25 April 2024): AutoStore Holdings Ltd (AutoStore, OSE:AUTO) today publishes its annual report for 2023. The report combines annual financial and sustainability reporting.   Throughout 2023, AutoStore focused on strategy and operational excellence to gain share in an underpenetrated market. The result was continued year-over-year revenue growth of 10.6 percent, increased market share and a return to historically high adjusted EBITDA margins of 47.8 percent.   During 2023, AutoStore reached 1,400 systems sold in total, delivered to 1,000 customers in 54 countries. In

AutoStore: Q1 2024 financial results

First quarter 2024 highlights (All comparisons to corresponding period in 2023) · Strong order intake of USD 183.0 million, up 11.4% YoY and up 11.7% QoQ · Driven largely by positive development in high throughput and MFC segments · Revenue of USD 138.1 million, -7.4% YoY, with lower shipments of large high throughput projects in line with expectations · Gross margin of 72.7%, driven by favorable product mix and price · Stable adj. EBITDA margin of 45.7% (45.8%)   (Nedre Vats, 25 April 2024): AutoStore Holdings Ltd. (AutoStore, OSE:AUTO), a robot technology company

OKEA ASA - First quarter 2024 financial results

(Trondheim, 25 April 2024) - OKEA ASA (OSE: OKEA) delivered operating income of NOK 3,474 (2,118) (correction from trading update of NOK 3,422) million and EBITDA of NOK 2,159 (1,661) million in the first quarter of 2024. The cash balance amounted to NOK 2,130 (2,301) million. An impairment charge of NOK 158 million was recognised in the quarter which comprises NOK 260 million of goodwill impairments from Statfjord, partly offset by NOK 102 million in reversal of previous impairments at Yme.(Amounts in parentheses refer to previous quarter) “The all-time high production in the quarter

Africa Oil Annual General Meeting to Be Held on May 23, 2024

VANCOUVER, BC, April 24, 2024 /CNW/ - (TSX – AOI, Nasdaq Stockholm - AOI) - Africa Oil Corp. (“Africa Oil” or the “Company”) announces that its Annual General Meeting of Shareholders will be held on Thursday, May 23, 2024 at 09:00 am (Pacific Time) at Bennett Jones LLP Fraser Boardroom, Park Place, 666 Burrard Street, Suite  2500, Vancouver V6C 2X8. The purpose of the Meeting is as follows: 1. To receive the consolidated audited financial statements and accompanying management’s discussion and analysis of the Company for the year ended December 31, 2023, together with the report of

Currency Rate for the upcoming Cash Dividend

With reference to the announcement made on 20 February 2024, the currency rate NOK/DKK to be used in the upcoming cash dividend is 0.6356. As previously announced, the proposed dividend payment for the Annual General Meeting on 30 April 2024 is DKK 8.70 per share. This corresponds to NOK 13.68785 per share. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Notice of Ordinary General Meeting of poLight ASA

The shareholders of poLight ASA are herby summoned to the Ordinary General Meeting on Wednesday 22 May 2024 at 12.30 hours, that will take place at the HQ's premises at Innlaget 5, 3185 Skoppum. Please find attached the notice of the Ordinary General Meeting together with and the attendance & proxy forms. Please also find attached the board of directors' remuneration report for salary and other remuneration for leading persons and the recommendation by the nomination committee. The Annual Report 2023 was published today and is available on the company's web site. The Notice and

Lehto Group Plc, inside information: Lehto's CEO is changing

Lehto Group PlcInsider information24 April 2024 at 11 p.m. (Finnish time)The board of Lehto Group Oyj ("Lehto") and CEO Juuso Hietanen have jointly agreed that Hietanen's CEO contract will expire on April 30, 2024. Hietanen will continue working for the company as an advisor until the end of May 2024, during which time Hietanen's key task will be to promote the sales and reorganization of the business parts of Lehto's subsidiary Lehto Components Oy. The company's board has appointed board member Hannu Lehto as CEO as of 1 May 2024. Hannu Lehto will continue in the board member role

Lytix Biopharma AS – Preliminary results in the share offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway, 24 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 9 and 10 April 2024, regarding the launch of a partially guaranteed share offering (the "

poLight ASA - Annual Report 2023

Horten, 24 April 2024 - poLight ASA (OSE: PLT) today the Board of Directors approved the 2023 Annual Report. The financial statements are consistent with the preliminary report disclosed on 27 February 2024. The board does not propose a dividend. Attached is the Annual Report 2023 for poLight ASA. The report is also available at www.polight.com. This stock exchange notice is subject to the disclosure requirements in Section 5-12 of the Norwegian Securities Trading Act.

Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines

Inside information Nanoform Finland Plc April 24, 2024 22.50 Finnish time / 21.50 Swedish time Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. With reference to the new share issue announced on

Insider information: Wetteri’s financing agreement has been renewed, Elo Mutual Employment Insurance Company as a new financier

Wetteri Plc Insider information 24 April 2024 at 21.15 EETOn 14 February 2024, Wetteri Plc announced that the covenants included in the financing agreement between the Themis Holding Oy subgroup, which is part of the Wetteri Group, and the financing bank had not been fully met.Wetteri has today received a notice from the financing bank that the bank will not exercise its right to demand immediate repayment of its receivables although the covenants were not fully met on 31 December 2023. Wetteri has also agreed with the financing bank to update the covenant terms of the financing agreement.

Everfuel: HySynergy update

Herning, Denmark, 24 April 2024 - Everfuel A/S today provides an update on the commissioning of the 20 MW HySynergy 1 electrolyser. The Company continues to progress commissioning focused on the sub-systems required to start production and delivery of green hydrogen. As previously communicated, the main electrolyser facility is ready for start-up, while some sub-systems experience delays following commissioning tests. This is impacting the planned start-up of the HySynergy 1 facility with production now expected to commence in the second half of 2024. Testing, verification and

Relesys A/S: Notification of transactions made by persons discharging managerial responsibilities and persons closely associated with them

Relesys A/S | Managers' transactionsCompany Announcement No. 5-2024Copenhagen, April 24, 2024In accordance with the EU’s Market Abuse Regulation article 19, Relesys A/S must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading of Relesys A/S shares. Relesys A/S hereby notify and submit the transactions of shares in Relesys A/S reflected in the attached forms. Reference is made to company announcement no. 4-2024 dated 24 April 2024 regarding the binding agreement entered

Bong Annual Report 2023

Bong’s Annual Report 2023 is now available at Bong’s website bong.com. For further information, please contact Carsten Grimmer, CFO for Bong AB.  Phone (switchboard) +46 44-20 70 00 This is information that Bong AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 19.15 CET on 24 April 2024. Bong is one of the leading providers of envelope products in Europe that also offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group

Calliditas Therapeutics’ 2023 Annual Report Published

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that the Annual Report for 2023 now is available at the company’s website: www.calliditas.comFor further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was sent for publication, through the agency of the contact persons set out above, on April 24,

Relesys A/S announces binding agreement with Copilot Capital Limited to acquire all outstanding shares in Relesys A/S for DKK 6.60 per share

Relesys A/S | Inside informationCompany Announcement No. 4-2024Outcome of strategic review for Relesys A/S Copenhagen, April 24, 2024Unite BidCo ApS, CVR-no. 44774739 ("BidCo"), a company controlled by funds advised by Copilot Capital Limited (“Copilot”), a private equity fund investing in European software champions, has entered into a binding transaction agreement relating to the acquisition of all outstanding shares in Relesys A/S ("Relesys") for DKK 6.60 per share representing a premium of 37% to the share price the day before Relesys announced the initiation of a strategic

Genetic Analysis AS: Notice of Annual General Meeting 2024

Oslo, Norway, April 24, 2024 - Notice is hereby served that the annual general meeting of Genetic Analysis AS (the "Company") will be held on Tuesday 14 May 2024 at 15:00 hours in the Company's premises in Ulvenveien 80, Oslo.Shareholders are encouraged to submit a proxy with voting instructions prior to the general meeting, see Appendix 2. Shareholders that still wish to participate in the general meeting are encouraged to notify the Company as stipulated in Appendix 1. Agenda: 1. Opening of the meeting 2. Election of a chairperson and a person to co-sign the minutes The

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on April 24, 2024, at 7:30 p.m. EESTMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On April 23, 2024, BlackRock's holding in Metso’s shares exceeded the 5 percent threshold and amounted to 41,631,044 shares or 5.02 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 647,285 shares, which corresponds to 0.07 percent of the total amount of Metso’s shares. On April

Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)

The shareholders of NextCell Pharma AB (publ), Reg. No. 556965-8361 (”NextCell” or the ”company”), are hereby summoned to an Extraordinary General Meeting on Monday, 27 May 2024, 10:00 CEST, in the Novum building, floor 6 (elevator E), Hälsovägen 7, SE-141 57 Huddinge, Sweden.Right to attend In order to attend the Extraordinary General Meeting, shareholders shall be registered in the share register kept by Euroclear Sweden AB as of 17 May 2024. Further, shareholders who wish to participate in the Extraordinary General Meeting must give notice of participation to the company no later than

Atlas Copco to utilize mandates to repurchase and sell shares

Nacka, Sweden, April 24, 2024: The Board of Atlas Copco AB has decided to use the mandates granted by the Annual General Meeting for the repurchase and sale of shares at one or more occasions until the next Annual General Meeting.The mandates cover: 1) The acquisition of not more than 10,000,000 series A shares related to personnel option plan for 2024, whereof a maximum of 8,000,000 may be transferred to option holders under the performance based personnel option plan 2024.2) The acquisition of not more than 60,000 series A shares, later to be sold on the market in connection with

There are no items matching the current filter
There are no more items matching the current filter
Back to top